Tissue Is the Issue for Novel Cancer Drug Discovery

Tissue standardization processes are of critical importance for advancing cancer research and is the basis on which Indivumed was founded over 20 years ago. Today, this standardization helps us perform whole-genome sequencing paired with whole transcriptome, miRNA, proteomics and phosphoproteomics data. This comprehensive dataset, based on tumor and normal tissue with 10–12 minutes of cold ischemia time, allows us to identify new therapeutic targets that others might miss. 

Read the complete article in Technology Network and find out more about our founder, our approach, and our goal to find therapeutically novel targets to push precision oncology forward.